Szőke, Dániel http://orcid.org/0000-0002-1095-3425
Kovács, Gábor http://orcid.org/0000-0002-6279-5131
Kemecsei, Éva
Bálint, László http://orcid.org/0000-0002-3142-4071
Szoták-Ajtay, Kitti
Aradi, Petra
Styevkóné Dinnyés, Andrea
Mui, Barbara L.
Tam, Ying K.
Madden, Thomas D.
Karikó, Katalin http://orcid.org/0000-0002-1864-3851
Kataru, Raghu P.
Hope, Michael J.
Weissman, Drew
Mehrara, Babak J.
Pardi, Norbert
Jakus, Zoltán http://orcid.org/0000-0002-6304-2369
Funding for this research was provided by:
Nemzeti Kutatási, Fejlesztési és Innovációs Hivatal (EFOP-3.6.3-VEKOP-16-2017-00009, EFOP-3.6.3-VEKOP-16-2017-00009)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01-AI050484, R01-AI124429, R01-AI084860, R01-AI050484, R01-AI124429, R01-AI084860, R01-AI146101)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
Article History
Received: 13 January 2019
Accepted: 30 April 2021
First Online: 8 June 2021
Competing interests
: In accordance with the University of Pennsylvania policies and procedures and our ethical obligations as researchers, we report that Katalin Karikó and Drew Weissman are named on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins. Drew Weissman and Norbert Pardi are also named on a patent describing the use of modified mRNA in lipid nanoparticles. We have disclosed those interests fully to the University of Pennsylvania, and we have in place an approved plan for managing any potential conflicts arising from licensing of our patents. No competing interests from other authors have been reported.